Skip to main content

Regulus Grosses a Total of $80.9M from Recent Transactions

Premium

Regulus Therapeutics this week announced that it grossed a total of $80.9 million from its recent initial public offering on the Nasdaq and other transactions.

The company went public in early October, floating its shares at $4 apiece, down from an originally expected $10 to $12 a share (GSN 10/4/2012). The total gross proceeds include $50.9 million from the public sale of common stock, $25 million from the sale of stock in a private placement with partner AstraZeneca, and $5 million from the sale of a convertible note in August to collaborator Biogen Idec.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.